Hancock Whitney’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.91M | Buy |
37,437
+280
| +0.8% | +$39.2K | 0.09% | 185 |
|
|
2025
Q4 | $4.56M | Sell |
37,157
-2,753
| -7% | -$335K | 0.08% | 184 |
|
|
2025
Q3 | $4.43M | Sell |
39,910
-8,631
| -18% | -$981K | 0.08% | 186 |
|
|
2025
Q2 | $5.38M | Buy |
48,541
+907
| +2% | +$96.5K | 0.1% | 153 |
|
|
2025
Q1 | $5.34M | Sell |
47,634
-634
| -1% | -$65.4K | 0.17% | 94 |
|
|
2024
Q4 | $4.46M | Sell |
48,268
-1,904
| -4% | -$171K | 0.14% | 110 |
|
|
2024
Q3 | $4.21M | Buy |
50,172
+5,688
| +13% | +$434K | 0.14% | 117 |
|
|
2024
Q2 | $3.05M | Sell |
44,484
-71,495
| -62% | -$4.77M | 0.1% | 139 |
|
|
2024
Q1 | $8.5M | Buy |
115,979
+6,050
| +6% | +$465K | 0.29% | 83 |
|
|
2023
Q4 | $8.91M | Buy |
109,929
+12,109
| +12% | +$942K | 0.33% | 72 |
|
|
2023
Q3 | $7.33M | Sell |
97,820
-980
| -1% | -$75.4K | 0.3% | 80 |
|
|
2023
Q2 | $7.62M | Sell |
98,800
-15,021
| -13% | -$1.2M | 0.3% | 82 |
|
|
2023
Q1 | $9.44M | Sell |
113,821
-28,846
| -20% | -$2.39M | 0.38% | 66 |
|
|
2022
Q4 | $12.2M | Sell |
142,667
-1,569
| -1% | -$124K | 0.47% | 51 |
|
|
2022
Q3 | $8.9M | Sell |
144,236
-4,008
| -3% | -$253K | 0.38% | 64 |
|
|
2022
Q2 | $9.16M | Buy |
148,244
+3,141
| +2% | +$194K | 0.37% | 70 |
|
|
2022
Q1 | $8.63M | Buy |
145,103
+2,544
| +2% | +$163K | 0.29% | 75 |
|
|
2021
Q4 | $10.4M | Sell |
142,559
-3,894
| -3% | -$268K | 0.33% | 71 |
|
|
2021
Q3 | $10.2M | Sell |
146,453
-3,729
| -2% | -$262K | 0.36% | 70 |
|
|
2021
Q2 | $10.3M | Buy |
150,182
+77,145
| +106% | +$5.15M | 0.33% | 73 |
|
|
2021
Q1 | $4.72M | Sell |
73,037
-1,942
| -3% | -$125K | 0.16% | 117 |
|
|
2020
Q4 | $4.37M | Sell |
74,979
-4,608
| -6% | -$278K | 0.15% | 123 |
|
|
2020
Q3 | $5.03M | Sell |
79,587
-9,215
| -10% | -$639K | 0.19% | 101 |
|
|
2020
Q2 | $6.83M | Buy |
88,802
+4,588
| +5% | +$352K | 0.26% | 85 |
|
|
2020
Q1 | $6.3M | Buy |
84,214
+35,878
| +74% | +$2.48M | 0.25% | 110 |
|
|
2019
Q4 | $3.14M | Buy |
48,336
+206
| +0.4% | +$13.4K | 0.1% | 234 |
|
|
2019
Q3 | $3.05M | Buy |
48,130
+17,017
| +55% | +$1.11M | 0.1% | 242 |
|
|
2019
Q2 | $2.1M | Sell |
31,113
-1,219
| -4% | -$80.2K | 0.07% | 294 |
|
|
2019
Q1 | $2.1M | Buy |
32,332
+2,465
| +8% | +$164K | 0.07% | 295 |
|
|
2018
Q4 | $1.87M | Buy |
29,867
+2,938
| +11% | +$205K | 0.06% | 307 |
|
|
2018
Q3 | $2.08M | Buy |
+26,929
| New | +$2.03M | 0.06% | 323 |
|
|
2016
Q3 | – | Sell |
-26,302
| Closed | -$2.19M | – | 562 |
|
|
2016
Q2 | $2.19M | Buy |
26,302
+584
| +2% | +$51.8K | 0.09% | 236 |
|
|
2016
Q1 | $2.36K | Buy |
25,718
+110
| +0.4% | +$9.92K | 0.1% | 240 |
|
|
2015
Q4 | $2.59M | Sell |
25,608
-1,480
| -5% | -$154K | 0.11% | 243 |
|
|
2015
Q3 | $2.66M | Buy |
27,088
+90
| +0.3% | +$10K | 0.11% | 236 |
|
|
2015
Q2 | $2.65M | Hold |
26,998
| – | – | 0.1% | 235 |
|
|
2015
Q1 | $2.65M | Sell |
26,998
-760
| -3% | -$77.2K | 0.1% | 235 |
|
|
2014
Q4 | $2.62M | Sell |
27,758
-680
| -2% | -$70.3K | 0.1% | 234 |
|
|
2014
Q3 | $3.03M | Buy |
+28,438
| New | +$2.78M | 0.12% | 217 |
|
Other funds holding GILD
VCM
VPM
Hancock Whitney's GILD Position: Q1 2026 in Review
Hancock Whitney increased its Gilead Sciences (GILD) stake by 0.75% in Q1 2026, buying an estimated $39.2K and bringing the position to 37,437 shares worth $4.91M. The position accounts for 0.09% of the portfolio, ranked #185.
Hancock Whitney first reported a position in GILD in Q3 2014 and has held it in 39 quarters since. The position peaked at $12.2M in Q4 2022. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Hancock Whitney held 37,437 shares of Gilead Sciences worth $4.91M as of Q1 2026.
- Hancock Whitney bought 280 Gilead Sciences shares in Q1 2026, an estimated $39.2K.
- Gilead Sciences made up 0.09% of Hancock Whitney's portfolio in Q1 2026, its #185 holding.
- Hancock Whitney first reported a position in Gilead Sciences in Q3 2014 and has held it in 39 quarters since.
- Hancock Whitney's Gilead Sciences position peaked at $12.2M in Q4 2022.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Hancock Whitney's 13F filing for Q1 2026, filed 15 May 2026.